Clinical trials: Malaria, Uncomplicated
Malaria
ACT MALI: Treatment of Malaria Based on Combination Therapies
Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence…
- Trial name
- NCT00452907
- Testing
- Artesunate, Artesunate + Sulfadoxine-Pyrimethamine, arthemether + lumefantrine
- Where
- Mali
- Volunteers
- 780 people
- Sponsor
- Sanofi
Malaria
Combination Antimalarials in Uncomplicated Malaria
The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or…
- Trial name
- NCT00203801
- Testing
- Sulfadoxine-pyrimethamine, Artesunate plus sulfadoxine-pyrimethamine, Artemether-lumefantrine
- Where
- 7 sites in Eswatini, Mozambique and 1 more
- Volunteers
- 700 people
- Sponsor
- University of Cape Town
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Malaria
A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)
Plasmodium vivax can form dormant liver stages that reactivate weeks or months following an acute infection. Recurrent infections can be associated with a febrile illness, a cumulative risk of severe anaemia, and even mortality.
- Trial name
- TRIPI (NCT02787070)
- Testing
- PQ supervised, PQ unsupervised
- Where
- Indonesia
- Volunteers
- 420 people
- Sponsor
- Menzies School of Health Research
Uncomplicated P. Falciparum Malaria in Children
Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso
Several countries in Africa have changed their first-line treatment for uncomplicated malaria to an ACT. Burkina Faso has changed its policy to Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (AQ+AS).
- Trial name
- ACTE (NCT01017770)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 4 sites in Burkina Faso
- Volunteers
- 340 people
- Sponsor
- Centre Muraz
Malaria
The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia
This is a two-arm, randomized, open label Treatment Study evaluating the therapeutic efficacy, safety, tolerability and pharmacokinetics of a three-day course of Atovaquone-Proguanil (AP) or a three-day course of…
- Trial name
- ASAP (NCT02297477)
- Testing
- atovaquone-proguanil, artesunate-atovaquone-proguanil
- Where
- Cambodia
- Volunteers
- 205 people
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger
Study treatments: Artemether-lumefantrine Artesunate-amodiaquine Dihydroartemisinin-piperaquine Location: Maradi, Niger Principal Objective: To measure the clinical and parasitological efficacy of the three artemisinin…
- Trial name
- NCT01755559
- Testing
- Artesunate-amodiaquine, Dihydroartemisinin-piperaquine, Artemether-lumefantrine
- Where
- Niger
- Volunteers
- 663 people
- Sponsor
- Epicentre
Malaria, Vivax
Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children
The main determinant of primaquine efficacy is the total dose of primaquine administered, rather than the dosing schedule. Infants and children younger than 4 years of age are at a higher risk of frequent relapses than older age…
- Trial name
- CHILDPRIM (NCT05044637)
- Testing
- Primaquine
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Malaria
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria
This study is being conducted to further evaluate the safety and clinical outcomes of Coartem® Baby (artemether/lumefantrine 5 mg/60 mg) in neonates and infants weighing ≥2 kg to <5 kg with uncomplicated malaria due to Plasmodium…
- Trial name
- NCT07713602
- Testing
- Coartem® Baby
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)
This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 4 sites of the two oral ACTS…
- Trial name
- MEFI_III (NCT04370977)
- Testing
- Coartem™ (Artemether-lumefantrine combination), Winthrop™ (Amodiaquine-artesunate combination)
- Where
- 6 sites in Mozambique
- Volunteers
- 630 people
- Sponsor
- Centro de Investigacao em Saude de Manhica
Plasmodium Falciparum
Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children
This open-label randomised controlled clinical trial will compare the safety, tolerability, therapeutic efficacy and pharmacokinetics and pharmacodynamics of arterolane-piperaquine, arterolane-piperaquine plus mefloquine versus…
- Trial name
- TACTKenya (NCT03452475)
- Testing
- Arterolane-piperaquine, Arterolane-piperaquine+mefloquine, Artemether-lumefantrine
- Where
- Kenya
- Volunteers
- 219 people
- Sponsor
- University of Oxford
Malaria
Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria
The present study aims to investigate and to assess possible neurological and neuropsychiatric events in young children in west Africa with uncomplicated P.
- Trial name
- NCT00978172
- Testing
- artesunate and mefloquine
- Where
- Cameroon
- Volunteers
- 220 people
- Sponsor
- Mepha Ltd.
Uncomplicated Malaria, Asymptomatic Condition
A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
Malaria is caused by protozoan parasites of the genus Plasmodium and it is the most important parasitic disease in terms of mortality and morbidity.
- Conditions
- Uncomplicated Malaria, Asymptomatic Condition, Falciparum Malaria
- Trial name
- ZYFER-1 (NCT05911828)
- Testing
- ZY19489 + Ferroquine (FQ)
- Where
- Gabon
- Volunteers
- 36 people
- Sponsor
- Zydus Lifesciences Limited
Malaria
Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo
The Democratic Republic of the Congo (DRC) is among the countries most affected by malaria in Sub-Saharan Africa. Condidering its size and the geographic position, the DRC is meant to play a major role in the malaria control in…
- Trial name
- TETRDC2016 (NCT02940756)
- Testing
- artesunate-amodiaquine, artemether-lumefantrine, Dihydroartemisinine-piperaquine
- Where
- 6 sites in Democratic Republic of the Congo
- Volunteers
- 1,615 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Malaria
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on D28 of administration of Coarsucam™ (artesunate+amodiaquine fixed-dose combination), as a single daily dose, in…
- Trial name
- NCT00316329
- Testing
- Artesunate + Amodiaquine
- Where
- 5 sites in Cameroon, Madagascar and 2 more
- Volunteers
- 1,032 people
- Sponsor
- Sanofi
Malaria, Severe Malaria
Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
Background: Malaria is caused by small parasites carried by some mosquitoes. People can get malaria if an infected mosquito bites them. Malaria destroys red blood cells.
- Trial name
- NCT01955382
- Testing
- Actidose Aqua, Artesunate, Amodiaquine
- Where
- Mali
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum
Randomized Trial on Effectiveness of ACTs in Ghana
The purpose of this study is to compare the effectiveness and safety of two Artemisinin Combination Therapies (ACTs) for the treatment of children with uncomplicated Plasmodium falciparum malaria
- Trial name
- NCT00374205
- Testing
- Artesunate plus Amodiaquine, Artemether-Lumefantrine
- Where
- Ghana
- Volunteers
- 245 people
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Malaria
Harmonized AS/MQ Efficacy Study - Thailand
The purposes of this study is to determine parasitological clearance rates by microscopy for the 72-hour period after first artesunate dose in subjects with uncomplicated P. falciparum malaria.
- Trial name
- NCT02052323
- Testing
- Artesunate/mefloquine (AS/MQ)
- Where
- Thailand
- Volunteers
- 48 people
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Malaria
Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum
This phase 2a open-label study to assess Meplazumab in adult patients diagnosed with Plasmodium falciparum
- Trial name
- NCT06040346
- Testing
- Meplazumab for Injection
- Where
- Kenya
- Volunteers
- 60 people
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd